Join Growin Stock Community!

Pyxis oncology, inc.PYXS.US Overview

US StockHealthcare
(No presentation for PYXS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PYXS AI Insights

PYXS Overall Performance

PYXS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PYXS Recent Performance

-2.38%

Pyxis oncology, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PYXS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PYXS Key Information

PYXS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PYXS Profile

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Price of PYXS

PYXS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PYXS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
32.46
PB Ratio
1.37
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-3442.77%
Revenue Growth (YoY)
-82.53%
Profit Growth (YoY)
-82.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
32.46
PB Ratio
1.37
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-3442.77%
Revenue Growth (YoY)
-82.53%
Profit Growth (YoY)
-82.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PYXS's latest earnings report released?

    The most recent financial report for Pyxis oncology, inc. (PYXS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PYXS's short-term business performance and financial health. For the latest updates on PYXS's earnings releases, visit this page regularly.

  • How much debt does PYXS have?

    As of the end of the reporting period, Pyxis oncology, inc. (PYXS) had total debt of 19.07M, with a debt ratio of 0.18. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PYXS have?

    At the end of the period, Pyxis oncology, inc. (PYXS) held Total Cash and Cash Equivalents of 10.39M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of PYXS?

    Pyxis oncology, inc. (PYXS)'s Free Cash Flow (FCF) for the period is -13.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 9.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PYXS?

    The latest valuation data shows Pyxis oncology, inc. (PYXS) has a Price-To-Earnings (PE) ratio of -2.44 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.